

# Anna Bershteyn

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5556308/anna-bershteyn-publications-by-citations.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54 papers	2,352 citations	21 h-index	48 g-index
65 ext. papers	2,876 ext. citations	8.7 avg, IF	4.52 L-index

#	Paper	IF	Citations
54	Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. <i>Nature Medicine</i> , <b>2010</b> , 16, 1035-41	50.5	489
53	Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. <i>Nature Materials</i> , <b>2011</b> , 10, 243-51	27	426
52	HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001245	11.6	284
51	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , <b>2013</b> , 2, 23-34	13.6	160
50	Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. <i>Lancet HIV</i> , <b>2020</b> , 7, e629-e640	7.8	147
49	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. <i>Nature</i> , <b>2015</b> , 528, S68-76	50.4	118
48	Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. <i>Journal of Controlled Release</i> , <b>2012</b> , 157, 354-65	11.7	79
47	Polymer-supported lipid shells, onions, and flowers. <i>Soft Matter</i> , <b>2008</b> , 4, 1787-1791	3.6	71
46	Nanobiomechanics of repair bone regenerated by genetically modified mesenchymal stem cells. <i>Tissue Engineering - Part A</i> , <b>2008</b> , 14, 1709-20	3.9	52
45	Sexual partnership age pairings and risk of HIV acquisition in rural South Africa. <i>Aids</i> , <b>2017</b> , 31, 1755-1764	3.5	44
44	Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era. <i>The Lancet Global Health</i> , <b>2015</b> , 3, e598-608	13.6	38
43	Implementation and applications of EMOD, an individual-based multi-disease modeling platform. <i>Pathogens and Disease</i> , <b>2018</b> , 76,	4.2	38
42	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 344-352	8	36
41	Age-dependent partnering and the HIV transmission chain: a microsimulation analysis. <i>Journal of the Royal Society Interface</i> , <b>2013</b> , 10, 20130613	4.1	35
40	Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 31888-901	5.4	33
39	Block copolymer micelles as nanocontainers for controlled release of proteins from biocompatible oil phases. <i>Biomacromolecules</i> , <b>2009</b> , 10, 732-41	6.9	31
38	Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding. <i>Biomacromolecules</i> , <b>2014</b> , 15, 2475-81	6.9	29

37	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. <i>EClinicalMedicine</i> , <b>2021</b> , 33, 100773	11.3	28
36	Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. <i>The Lancet Global Health</i> , <b>2020</b> , 8, e1305-e1315	13.6	25
35	Dropout and re-enrollment: implications for epidemiological projections of treatment programs. <i>Aids</i> , <b>2014</b> , 28 Suppl 1, S47-59	3.5	23
34	Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2020</b> , 21, 475	2.8	21
33	Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. <i>Health and Place</i> , <b>2019</b> , 57, 339-351	4.6	17
32	Evidence of sociodemographic heterogeneity across the HIV treatment cascade and progress towards 90-90-90 in sub-Saharan Africa - a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23, e25470	5.4	13
31	Age-targeted HIV treatment and primary prevention as a time fence to efficiently interrupt the age patterns of transmission in generalized epidemic settings in South Africa. <i>International Health</i> , <b>2016</b> , 8, 277-85	2.4	13
30	The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study. <i>Lancet HIV</i> , <b>2020</b> , 7, e348-e358	7.8	11
29	Targeting HIV services to male migrant workers in southern Africa would not reverse generalized HIV epidemics in their home communities: a mathematical modeling analysis. <i>International Health</i> , <b>2015</b> , 7, 107-13	2.4	11
28	Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. <i>Vaccine</i> , <b>2019</b> , 37, 2258-2267	4.1	8
27	Geographic coverage of male circumcision in western Kenya. <i>Medicine (United States)</i> , <b>2017</b> , 96, e5885	1.8	8
26	The influence of mobility among high-risk populations on HIV transmission in Western Kenya. <i>Infectious Disease Modelling</i> , <b>2018</b> , 3, 97-106	15.7	7
25	Association between economic growth and early childhood nutrition. <i>The Lancet Global Health</i> , <b>2015</b> , 3, e79-80	13.6	6
24	Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. <i>Lancet HIV</i> , <b>2021</b> , 8, e216-e224	7.8	6
23	Which policies most effectively reduce SARS-CoV-2 transmission in schools?		5
22	Demographic and risk group heterogeneity across the UNAIDS 90-90-90 targets: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , <b>2019</b> , 8, 110	3	4
21	The Risks and Benefits of Providing HIV Services during the COVID-19 Pandemic		4
20	The future of a partially effective HIV vaccine: assessing limitations at the population level. <i>International Journal of Public Health</i> , <b>2019</b> , 64, 957-964	4	3

19	The risks and benefits of providing HIV services during the COVID-19 pandemic.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0260820	3.7	3
18	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244761	3.7	3
17	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2142796	10.4	2
16	Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23 Suppl 3, e25527	5.4	2
15	Large age shifts in HIV-1 incidence patterns in KwaZulu-Natal, South Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	2
14	Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2148325	10.4	2
13	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.. <i>Lancet HIV,the</i> , <b>2022</b> , 9, e353-e362	7.8	2
12	Intensive Care Unit Capacity and Its Associated Risk Factors During the COVID-19 Surge in the Republic of Korea: Analysis Using Nationwide Health Claims Data. <i>Risk Management and Healthcare Policy</i> , <b>2020</b> , 13, 2571-2581	2.8	1
11	Taking a stand against the politicization of medical research: how Twinging the pendulumTposes a hazard to clinical trials, study participants, and the progress of science. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 101-103	5.1	1
10	Modeling the Impact of Targeting Treatment and Prevention to the Migrant Population of Male Miners in a Generalized Epidemic Setting. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, A260-A260	1.6	
9	Long-term Risk of HIV Drug Resistance after PrEP Breakthrough Infection: Implications from a Mathematical Model of the HIV Latent Reservoir. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, A162-A162	1.6	
8	LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S851-S852	1	
7	Policy Review and Modeling Analysis of Mitigation Measures for Coronavirus Disease Epidemic Control, Health System, and Disease Burden, South Korea. <i>Emerging Infectious Diseases</i> , <b>2021</b> , 27, 2753-2760	10.2	
6	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision <b>2020</b> , 15, e0244761		
5	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision <b>2020</b> , 15, e0244761		
4	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision <b>2020</b> , 15, e0244761		
3	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision <b>2020</b> , 15, e0244761		
2	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision <b>2020</b> , 15, e0244761		

- 1 Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision **2020**, 15, e0244761